Stock Track | AxoGen Soars 5.13% in Pre-market on Raised 2026 Revenue Outlook and Analyst Buy Rating

Stock Track05-04

AxoGen's stock surged 5.13% during pre-market trading on Monday, indicating strong investor interest ahead of the regular session.

The pre-market rally appears to be driven by the company's recently raised 2026 financial outlook and positive analyst sentiment. AxoGen reported first-quarter 2026 results that showed significant sales growth but a wider net loss, while simultaneously raising its full-year guidance to project at least 20% revenue growth to approximately $270 million with improved gross margins.

Adding to the positive momentum, Canaccord Genuity reiterated its Buy rating on AxoGen with a $50 price target, reinforcing confidence in the company's nerve repair platform and its post-FDA approval transition for its Avance product.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136725082?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-04 20:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136725082","market":"nz","top_or_hot":-1,"title":"Stock Track | AxoGen Soars 5.13% in Pre-market on Raised 2026 Revenue Outlook and Analyst Buy Rating","media":"Stock Track","content":"<p>AxoGen's stock surged 5.13% during pre-market trading on Monday, indicating strong investor interest ahead of the regular session.</p><p>The pre-market rally appears to be driven by the company's recently raised 2026 financial outlook and positive analyst sentiment. AxoGen reported first-quarter 2026 results that showed significant sales growth but a wider net loss, while simultaneously raising its full-year guidance to project at least 20% revenue growth to approximately $270 million with improved gross margins.</p><p>Adding to the positive momentum, Canaccord Genuity reiterated its Buy rating on AxoGen with a $50 price target, reinforcing confidence in the company's nerve repair platform and its post-FDA approval transition for its Avance product.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AxoGen Soars 5.13% in Pre-market on Raised 2026 Revenue Outlook and Analyst Buy Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AxoGen Soars 5.13% in Pre-market on Raised 2026 Revenue Outlook and Analyst Buy Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-04 20:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AxoGen's stock surged 5.13% during pre-market trading on Monday, indicating strong investor interest ahead of the regular session.</p><p>The pre-market rally appears to be driven by the company's recently raised 2026 financial outlook and positive analyst sentiment. AxoGen reported first-quarter 2026 results that showed significant sales growth but a wider net loss, while simultaneously raising its full-year guidance to project at least 20% revenue growth to approximately $270 million with improved gross margins.</p><p>Adding to the positive momentum, Canaccord Genuity reiterated its Buy rating on AxoGen with a $50 price target, reinforcing confidence in the company's nerve repair platform and its post-FDA approval transition for its Avance product.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AXGN","symbol_name":"AxoGen Inc.","start_time":0,"source_url":"","article_id":"1136725082","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136725082","pubTimestamp":1777899155,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AxoGen's stock surged 5.13% during pre-market trading on Monday, indicating strong investor interest ahead of the regular session.The pre-market rally appears to be driven by the company's recently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AXGN":"AxoGen Inc."},"translate_title":"个股追踪|AxoGen盘前飙升5.13%，因上调2026年营收预期和分析师买入评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXGN":1},"content_text":"AxoGen's stock surged 5.13% during pre-market trading on Monday, indicating strong investor interest ahead of the regular session.The pre-market rally appears to be driven by the company's recently raised 2026 financial outlook and positive analyst sentiment. AxoGen reported first-quarter 2026 results that showed significant sales growth but a wider net loss, while simultaneously raising its full-year guidance to project at least 20% revenue growth to approximately $270 million with improved gross margins.Adding to the positive momentum, Canaccord Genuity reiterated its Buy rating on AxoGen with a $50 price target, reinforcing confidence in the company's nerve repair platform and its post-FDA approval transition for its Avance product.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136725082","isCrawlerRequest":true}